Prognosis and survival evaluation in treating high-risk BRAF V600 mutation stage III or IV melanoma with dabrafenib plus trametinib therapy: A meta-analysis of 2,660 patients
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
LIPPINCOTT WILLIAMS \& WILKINS
Abstract
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acceso abierto (Metadatos de producción científica)